文献速递临床微生物分子诊断

CLSI M45 非铜绿假单胞菌假单胞菌属药敏试验方法与折点建立

Establishing Clinical and Laboratory Standards Institute M45 antimicrobial susceptibility testing methods and breakpoints for Pseudomonas other than Pseudomonas aeruginosa.
PubMed 文献 · J Clin Microbiol · 2025-06-30

本研究旨在建立 CLSI M45 对非铜绿假单胞菌假单胞菌属(POPA)的暂定 MIC 和纸片扩散法折点,并评估耐药机制及 mCIM 检测碳青霉烯酶的性能。基于 2013–2022 年 MIC 数据比较 POPA 与铜绿假单胞菌的分布,用 83 株菌完成纸片-MIC 相关性研究建立折点;CLSI M45 委员会据此提出头孢他啶、头孢吡肟、美罗培南、亚胺培南、环丙沙星、左氧氟沙星、阿米卡星和妥布霉素的暂定折点。

要点

  • CLSI M45 提出 POPA 对头孢他啶、头孢吡肟、美罗培南、亚胺培南、环丙沙星、左氧氟沙星、阿米卡星和妥布霉素的暂定 MIC 与纸片扩散折点。
  • mCIM 检测碳青霉烯酶在 POPA 中灵敏度和特异度均为 100%。
  • 多数抗菌药物 POPA 与铜绿假单胞菌的模态 MIC 相差在 1 个倍比稀释内,阿米卡星低 2 个倍比稀释。

核心结论

  • CLSI M45 委员会针对 POPA 提出了头孢他啶、头孢吡肟、美罗培南、亚胺培南、环丙沙星、左氧氟沙星、阿米卡星和妥布霉素的暂定 MIC 和纸片扩散折点。

研究设计与样本

  • 研究评估 2013 至 2022 年铜绿假单胞菌与 POPA 的 MIC 数据,比较 MIC 分布和模态 MIC 与 CLSI M100 铜绿假单胞菌折点的关系。
  • 用 83 株菌完成纸片扩散与参考肉汤微量稀释法的相关性研究,采用误差率界定法建立纸片扩散折点。
  • 通过全基因组测序鉴定耐药基因,并评估 mCIM 检测碳青霉烯酶产生的性能。

主要发现

  • 对多数抗菌药物,铜绿假单胞菌与 POPA 的模态 MIC 相差在 1 个倍比稀释内,且低于 M100 铜绿假单胞菌敏感折点。
  • 阿米卡星的 POPA 模态 MIC 比铜绿假单胞菌低 2 个倍比稀释,并参照肠杆菌目折点进行评估。
  • 氨曲南和甲氧苄啶-磺胺甲噁唑的模态 MIC 升高,未设定折点。
  • 除氟喹诺酮类外,多数抗菌药物建立了新的纸片扩散相关性;氟喹诺酮类沿用铜绿假单胞菌的纸片扩散相关性。
  • 30 株(36.1%)分离株检出 β-内酰胺酶基因,其中金属 β-内酰胺酶占 90.6%;mCIM 灵敏度和特异度均为 100%。

关键数值与推荐

  • CLSI M45 委员会提出头孢他啶、头孢吡肟、美罗培南、亚胺培南、环丙沙星、左氧氟沙星、阿米卡星和妥布霉素的暂定 MIC 与纸片扩散折点。
  • β-内酰胺酶基因在 30 株(36.1%)分离株中检出,金属 β-内酰胺酶占 90.6%。
  • mCIM 检测碳青霉烯酶产生的灵敏度和特异度均为 100%。

临床怎么用

  • 临床微生物实验室可参照 CLSI M45 暂定折点对 POPA 进行 MIC 或纸片扩散法药敏试验。
  • 对 POPA 碳青霉烯类耐药株,可采用 mCIM 检测碳青霉烯酶产生。
  • 氨曲南和甲氧苄啶-磺胺甲噁唑因模态 MIC 升高,CLSI M45 未设定折点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The purpose of this study was to establish tentative Clinical and Laboratory Standards Institute (CLSI) M45 MIC and disk diffusion (DD) breakpoints (BPs) for Pseudomonas other than Pseudomonas aeruginosa (POPA). Mechanisms of antimicrobial resistance (AMR) and the modified carbapenem inactivation method (mCIM) to detect carbapenemase production were also evaluated. MIC data from P. aeruginosa and POPA from 2013 to 2022 were evaluated to compare the MIC distributions and modal MICs relative to the CLSI M100 P. aeruginosa BPs. A disk-to-MIC correlation study with 83 isolates was completed by testing reference broth microdilution and DD from the same inoculum, and the error-rate bounded method was used to establish DD BPs. For most antimicrobials, the modal MICs between P. aeruginosa and POPA were within 1-doubling dilution and lower than the M100 P. aeruginosa-susceptible BP. For amikacin, the modal MIC for POPA was 2-doubling dilutions lower than P. aeruginosa and was evaluated relative to the Enterobacterales BP. For aztreonam and trimethoprim-sulfamethoxazole, the modal MICs were elevated, and no BPs were set. New DD correlates were established for most antimicrobial agents, except for fluoroquinolones, where the P. aeruginosa correlates were suitable. AMR genes conferring resistance to multiple antimicrobial classes were identified by WGS. Beta-lactamase genes were identified in 30 (36.1%) isolates, with metallo-beta-lactamases (90.6%) predominating. The mCIM had a sensitivity and specificity of 100%. Upon review, the CLSI M45 committee proposed tentative MIC and DD BPs for expanded-spectrum cephalosporins (ceftazidime and cefepime), carbapenems (meropenem and imipenem), fluoroquinolones (ciprofloxacin and levofloxacin), and the aminoglycosides (amikacin and tobramycin).IMPORTANCEPseudomonas species other than Pseudomonas aeruginosa (POPA) can cause opportunistic infections which may be difficult to treat due to a variety of antimicrobial resistance mechanisms. Antimicrobial susceptibility testing is a critical component of patient management for these infections. Currently, the Clinical and Laboratory Standards Institute (CLSI) M100 non-Enterobacterales breakpoints and methodology are utilized for POPA by US clinical laboratories and likely do not accurately predict susceptibility results. The purpose of this study was to establish tentative CLSI M45 MIC and disk diffusion breakpoints for POPA. Mechanisms of antimicrobial resistance and the modified carbapenem inactivation method to detect carbapenemase production were also evaluated. We present the data used by the volunteers tasked by CLSI to develop POPA breakpoints in the M45 guidelines.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Simner PJ, Harris H, Jacobs E, et al. Establishing Clinical and Laboratory Standards Institute M45 antimicrobial susceptibility testing methods and breakpoints for Pseudomonas other than Pseudomonas aeruginosa. J Clin Microbiol. 2025. PMID: 40586600. doi:10.1128/jcm.00368-25

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。